Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.56 |
| ▸ | BACE1 | P56817 | 6/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972923 | 0.91 | NAALAD2 (0.53) | BACE1NTSR2NTSR1BACE2 | |
| SCHEMBL31482342 | 0.89 | FOLH1 (0.57) | NTSR2NTSR1OPRM1OPRD1NPY1R | |
| SCHEMBL29369469 | 0.89 | FOLH1 (0.57) | NTSR2NTSR1OPRM1OPRD1NPY1R | |
| SCHEMBL29531691 | 0.88 | NPY4R (0.59) | BACE1BACE2OPRD1NPY1RNPY2R | |
| SCHEMBL31226890 | 0.88 | KISS1R (0.54) | KISS1RBACE1NTSR2NTSR1BACE2 | |
| SCHEMBL31696338 | 0.88 | BACE1 (0.67) | KISS1RBACE1BACE2 | |
| SCHEMBL18905180 | 0.87 | BACE1 (0.52) | KISS1RBACE1NTSR2NTSR1BACE2 | |
| SCHEMBL29857400 | 0.87 | ACE (0.51) | KISS1RBACE1BACE2OPRM1OPRD1 | |
| SCHEMBL29458786 | 0.87 | ACE (0.51) | KISS1RBACE1BACE2OPRM1OPRD1 | |
| SCHEMBL11886068 | 0.87 | ACE (0.51) | KISS1RBACE1BACE2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2024-06-27 | — | — | US | claimed |
| US-11814417-B2 | GIP agonist compounds and methods | ZEALAND PHARMA A/S (DK) | 2023-11-14 | — | — | US | claimed |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | KISS1R 129/4885BACE1 3779/4885NTSR2 52/4885 |
| US-11814417-B2 | GIP agonist compounds and methods | GIPR, GLP1R, GPR119 | KISS1R 129/4885BACE1 3779/4885NTSR2 52/4885 |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | KISS1R 129/4885BACE1 3779/4885NTSR2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.